COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects

David M Smadja, Steven J Mentzer, Michaela Fontenay, Mike A Laffan, Maximilian Ackermann, Julie Helms, Danny Jonigk, Richard Chocron, Gerald B Pier, Nicolas Gendron, Stephanie Pons, Jean-Luc Diehl, Coert Margadant, Coralie Guerin, Elisabeth J M Huijbers, Aurélien Philippe, Nicolas Chapuis, Patrycja Nowak-Sliwinska, Christian Karagiannidis, Olivier Sanchez, Philipp Kümpers, David Skurnik, Anna M Randi, Arjan W Griffioen, David M Smadja, Steven J Mentzer, Michaela Fontenay, Mike A Laffan, Maximilian Ackermann, Julie Helms, Danny Jonigk, Richard Chocron, Gerald B Pier, Nicolas Gendron, Stephanie Pons, Jean-Luc Diehl, Coert Margadant, Coralie Guerin, Elisabeth J M Huijbers, Aurélien Philippe, Nicolas Chapuis, Patrycja Nowak-Sliwinska, Christian Karagiannidis, Olivier Sanchez, Philipp Kümpers, David Skurnik, Anna M Randi, Arjan W Griffioen

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is presenting as a systemic disease associated with vascular inflammation and endothelial injury. Severe forms of SARS-CoV-2 infection induce acute respiratory distress syndrome (ARDS) and there is still an ongoing debate on whether COVID-19 ARDS and its perfusion defect differs from ARDS induced by other causes. Beside pro-inflammatory cytokines (such as interleukin-1 β [IL-1β] or IL-6), several main pathological phenomena have been seen because of endothelial cell (EC) dysfunction: hypercoagulation reflected by fibrin degradation products called D-dimers, micro- and macrothrombosis and pathological angiogenesis. Direct endothelial infection by SARS-CoV-2 is not likely to occur and ACE-2 expression by EC is a matter of debate. Indeed, endothelial damage reported in severely ill patients with COVID-19 could be more likely secondary to infection of neighboring cells and/or a consequence of inflammation. Endotheliopathy could give rise to hypercoagulation by alteration in the levels of different factors such as von Willebrand factor. Other than thrombotic events, pathological angiogenesis is among the recent findings. Overexpression of different proangiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF-2) or placental growth factors (PlGF) have been found in plasma or lung biopsies of COVID-19 patients. Finally, SARS-CoV-2 infection induces an emergency myelopoiesis associated to deregulated immunity and mobilization of endothelial progenitor cells, leading to features of acquired hematological malignancies or cardiovascular disease, which are discussed in this review. Altogether, this review will try to elucidate the pathophysiology of thrombotic complications, pathological angiogenesis and EC dysfunction, allowing better insight in new targets and antithrombotic protocols to better address vascular system dysfunction. Since treating SARS-CoV-2 infection and its potential long-term effects involves targeting the vascular compartment and/or mobilization of immature immune cells, we propose to define COVID-19 and its complications as a systemic vascular acquired hemopathy.

Conflict of interest statement

CK reports personal fees from Maquet, Xenios, and Bayer, as well as non-financial support from Speaker of the German register of ICUs and grants from the German Ministry of Research and Education.

© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Figures

Fig. 1
Fig. 1
Pathophysiology for microthrombosis in patients with COVID-19. The figure summarizes hypothetical steps of the thrombotic sequence from direct or indirect of SARS-CoV-2 effects on endothelial cells inducing an endotheliopathy and a coagulopathy leading to lung obstruction and potential consequences on the right heart ventricle
Fig. 2
Fig. 2
Autopsy studies of patients dying of COVID-19. a Hematoxylin and eosin histology demonstrated perivascular lymphocytic infiltration (10X, bar = 100um). b Higher resolution (60X) imaging of the alveolar septa demonstrating microthrombus in alveolar capillaries (black arrows). c Scanning electron microscopy of the COVID-19 lung demonstrating preserved architecture with perivascular and interstitial lymphocytes. Intravascular thrombus was visualized in many vessels (white arrows; bar = 200um). d Corrosion casting demonstrating luminal irregularities associated with endothelial injury and endothelialitis. In the affected microcirculation, innumerable intraluminal pillars (circles), seen as small holes in the cast, reflect the process of intussusceptive angiogenesis (bar = 100um)
Fig. 3
Fig. 3
Intussusceptive angiogenesis: hypothesis for lung vessels modification in COVID-19
Fig. 4
Fig. 4
Emergency myelopoiesis. Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) released by damaged tissues after the pathogen insult are sensed by tissue-resident macrophages, hematopoietic stem and progenitor cells (HSPC), mesenchymal stroma cells (MSC) and endothelial cells (EC) via the pattern recognition receptors ie Toll-like receptors. These cells release inflammatory cytokines forcing the proliferation and differentiation of HSPC into granulocyte-monocyte progenitors (GMP), which produce neutrophils and monocytes with immunosuppressive phenotype. In severe COVID-19, immature neutrophils and dysfunctional monocytes that resemble myeloid-derived suppressive cells produce high amounts of calprotectin, which in turn amplifies the emergency myelopoiesis. IL-1: interleukin 1, IL-6: interleukin 6, IFN-γ: interferon γ, GM-CSF: granulo-monocyte colony-stimulating factor, G-CSF: granulocyte colony-stimulating factor, M-CSF: monocyte colony-stimulating factor

References

    1. Debuc B, Smadja DM. Is COVID-19 a new hematologic disease? Stem Cell Rev Rep. 2021;17(1):4–8. doi: 10.1007/s12015-020-09987-4.
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center For Disease Control And Prevention. JAMA. 2020;323(13):1239–1242. doi: 10.1001/jama.2020.2648.
    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032.
    1. Diehl JL, Peron N, Chocron R, Debuc B, Guerot E, Hauw-Berlemont C, et al. Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a hypothesis-generating study. Ann Intensive Care. 2020;10(1):95. doi: 10.1186/s13613-020-00716-1.
    1. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8(9):853–862. doi: 10.1016/S2213-2600(20)30316-7.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032. doi: 10.1038/s41591-020-0968-3.
    1. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi: 10.1182/blood.2020006000.
    1. Helms J, Severac F, Merdji H, Angles-Cano E, Meziani F. Prothrombotic phenotype in COVID-19 severe patients. Intensive Care Med. 2020;46(7):1502–1503. doi: 10.1007/s00134-020-06082-7.
    1. Shah A, Donovan K, McHugh A, Pandey M, Aaron L, Bradbury CA, et al. Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study. Crit Care. 2020;24(1):561. doi: 10.1186/s13054-020-03260-3.
    1. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–150. doi: 10.1016/j.thromres.2020.04.041.
    1. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi: 10.1016/j.thromres.2020.04.013.
    1. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020;142(2):184–186. doi: 10.1161/CIRCULATIONAHA.120.047430.
    1. Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575–e582. doi: 10.1016/S2352-3026(20)30216-7.
    1. Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet. 2020;396(10247):320–332. doi: 10.1016/S0140-6736(20)31305-2.
    1. Mentzer SJ, Konerding MA. Intussusceptive angiogenesis: expansion and remodeling of microvascular networks. Angiogenesis. 2014;17(3):499–509. doi: 10.1007/s10456-014-9428-3.
    1. Helms J, Severac F, Merdji H, Angles-Cano E, Meziani F. Prothrombotic phenotype in COVID-19 severe patients. Intensive Care Med. 2020;46:1502–1505. doi: 10.1007/s00134-020-06082-7.
    1. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382(25):e102. doi: 10.1056/NEJMoa2007621.
    1. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med. 2020;382(17):e38. doi: 10.1056/NEJMc2007575.
    1. Jonigk D, Markl B, Helms J. COVID-19: what the clinician should know about post-mortem findings. Intensive Care Med. 2021;47(1):86–89. doi: 10.1007/s00134-020-06302-0.
    1. Planquette B, Le Berre A, Khider L, Yannoutsos A, Gendron N, de Torcy M, et al. Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: a nested case-control study. Thromb Res. 2021;197:94–99. doi: 10.1016/j.thromres.2020.11.001.
    1. Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173(4):268–277. doi: 10.7326/M20-2003.
    1. Jimenez D, Garcia-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest. 2020;150:1182–1196.
    1. Suh YJ, Hong H, Ohana M, Bompard F, Revel MP, Valle C, et al. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2020 doi: 10.1148/radiol.2020203557.
    1. Zhang R, Ni L, Di X, Wang X, Ma B, Niu S, et al. Prevalence of venous thromboembolic events in novel coronavirus disease-2019 patients: systematic review and meta-analysis. J Vasc Surg Venous Lymphatic Disorders. 2020 doi: 10.1016/j.jvsv.2020.11.023.
    1. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639. doi: 10.1016/j.eclinm.2020.100639.
    1. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5.
    1. Delabranche X, Quenot JP, Lavigne T, Mercier E, Francois B, Severac F, et al. Early detection of disseminated intravascular coagulation during septic shock: a multicenter prospective study. Crit Care Med. 2016;44(10):e930–e939. doi: 10.1097/CCM.0000000000001836.
    1. Iba T, Di Nisio M, Thachil J, Wada H, Asakura H, Sato K, et al. Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Crit Care. 2016;20:287. doi: 10.1186/s13054-016-1468-1.
    1. Taylor FB, Jr, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation of the International Society on T, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–1330. doi: 10.1055/s-0037-1616068.
    1. Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med. 2013;41(9):2069–2079. doi: 10.1097/CCM.0b013e31828e9b03.
    1. Helms J, Severac F, Merdji H, Clere-Jehl R, Francois B, Mercier E, et al. Performances of disseminated intravascular coagulation scoring systems in septic shock patients. Ann Intensive Care. 2020;10(1):92. doi: 10.1186/s13613-020-00704-5.
    1. Khinda J, Janjua NZ, Cheng S, van den Heuvel ER, Bhatti P, Darvishian M. Association between markers of immune response at hospital admission and COVID-19 disease severity and mortality: a meta-analysis and meta-regression. J Med Virol. 2021;93(2):1078–1098. doi: 10.1002/jmv.26411.
    1. Goudot G, Chocron R, Augy JL, Gendron N, Khider L, Debuc B, et al. Predictive factor for COVID-19 worsening: insights for high-sensitivity troponin and D-dimer and correlation with right ventricular afterload. Front Med (Lausanne). 2020;7:586307. doi: 10.3389/fmed.2020.586307.
    1. Khider L, Gendron N, Goudot G, Chocron R, Hauw-Berlemont C, Cheng C, et al. Curative anticoagulation prevents endothelial lesion in COVID-19 patients. J Thromb Haemost. 2020;18(9):2391–2399. doi: 10.1111/jth.14968.
    1. Chocron R, Duceau B, Gendron N, Ezzouhairi N, Khider L, Trimaille A, et al. D-dimer at hospital admission for COVID-19 are associated with in-hospital mortality, independent of venous thromboembolism: Insights from a French multicenter cohort study. Arch Cardiovasc Dis. 2021 doi: 10.1016/j.acvd.2021.02.003.
    1. Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, et al. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit Care. 2020;24(1):364. doi: 10.1186/s13054-020-03000-7.
    1. Delabranche X, Helms J, Meziani F. Immunohaemostasis: a new view on haemostasis during sepsis. Ann Intensive Care. 2017;7(1):117. doi: 10.1186/s13613-017-0339-5.
    1. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590. doi: 10.1007/s00134-020-05985-9.
    1. Remmelink M, De Mendonca R, D'Haene N, De Clercq S, Verocq C, Lebrun L, et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit Care. 2020;24(1):495. doi: 10.1186/s13054-020-03218-5.
    1. Grimmer B, Kuebler WM. The endothelium in hypoxic pulmonary vasoconstriction. J Appl Physiol (1985) 2017;123(6):1635–1646. doi: 10.1152/japplphysiol.00120.2017.
    1. Yan SF, Mackman N, Kisiel W, Stern DM, Pinsky DJ. Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol. 1999;19(9):2029–2035. doi: 10.1161/01.ATV.19.9.2029.
    1. Gupta N, Zhao YY, Evans CE. The stimulation of thrombosis by hypoxia. Thromb Res. 2019;181:77–83. doi: 10.1016/j.thromres.2019.07.013.
    1. Gendron N, Dragon-Durey MA, Chocron R, Darnige L, Jourdi G, Philippe A, et al. Lupus anticoagulant single positivity at acute phase is not associated with venous thromboembolism or in-hospital mortality in COVID-19. Arthritis Rheumatol. 2021 doi: 10.1002/art.41777.
    1. Oudemans-van Straaten HM. Hemostasis and thrombosis in continuous renal replacement treatment. Semin Thromb Hemost. 2015;41(1):91–98. doi: 10.1055/s-0034-1398384.
    1. Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747–1751. doi: 10.1111/jth.14854.
    1. Nougier C, Benoit R, Simon M, Desmurs-Clavel H, Marcotte G, Argaud L, et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost. 2020;18(9):2215–2219. doi: 10.1111/jth.15016.
    1. Maatman TK, Jalali F, Feizpour C, Douglas A, 2nd, McGuire SP, Kinnaman G, et al. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019. Crit Care Med. 2020;48(9):e783–e790. doi: 10.1097/CCM.0000000000004466.
    1. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738–1742. doi: 10.1111/jth.14850.
    1. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998–1000. doi: 10.1055/s-0040-1710018.
    1. Weiss E, Roux O, Moyer JD, Paugam-Burtz C, Boudaoud L, Ajzenberg N, et al. Fibrinolysis resistance: a potential mechanism underlying COVID-19 coagulopathy. Thromb Haemost. 2020;120(9):1343–1345. doi: 10.1055/s-0040-1713637.
    1. Hattori N, Sisson TH, Xu Y, Desai TJ, Simon RH. Participation of urokinase-type plasminogen activator receptor in the clearance of fibrin from the lung. Am J Physiol. 1999;277(3):L573–L579.
    1. Bajou K, Herkenne S, Thijssen VL, D'Amico S, Nguyen N-Q-N, Bouché A, Tabruyn S, Srahna M, Carabin J-Y, Nivelles O, Paques C, Cornelissen I, Lion M, Noel A, Gils A, Vinckier S, Declerck PJ, Griffioen AW, Dewerchin M, Martial JA, Carmeliet P, Struman I. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nature Medicine. 2014;20(7):741–747. doi: 10.1038/nm.3552.
    1. Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsky MS. Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation. 2002;106(18):2372–2378. doi: 10.1161/.
    1. Flevaris P, Vaughan D. The role of plasminogen activator inhibitor type-1 in fibrosis. Semin Thromb Hemost. 2017;43(02):169–177. doi: 10.1055/s-0036-1586228.
    1. Yang L-L, Yang T. Pulmonary rehabilitation for patients with coronavirus disease 2019 (COVID-19) Chronic Dis Transl Med. 2020;6(2):79–86.
    1. Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S, et al. Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020 doi: 10.1016/j.jamcollsurg.2020.05.007.
    1. Gue YX, Gorog DA. Importance of endogenous fibrinolysis in platelet thrombus formation. Int J Mol Sci. 2017 doi: 10.3390/ijms18091850.
    1. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest. 1989;84(2):695–705. doi: 10.1172/JCI114217.
    1. Undas A, Natorska J. Improving fibrinolysis in venous thromboembolism: impact of fibrin structure. Expert Rev Hematol. 2019;12(8):597–607. doi: 10.1080/17474086.2019.1627193.
    1. Kruse JM, Magomedov A, Kurreck A, Münch FH, Koerner R, Kamhieh-Milz J, et al. Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. Crit Care. 2020;24(1):676. doi: 10.1186/s13054-020-03401-8.
    1. Thachil J, Juffermans NP, Ranucci M, Connors JM, Warkentin TE, Ortel TL, et al. ISTH DIC subcommittee communication on anticoagulation in COVID-19. J Thromb Haemost. 2020;18(9):2138–2144. doi: 10.1111/jth.15004.
    1. Jonmarker S, Hollenberg J, Dahlberg M, Stackelberg O, Litorell J, Everhov AH, et al. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. Crit Care. 2020;24(1):653. doi: 10.1186/s13054-020-03375-7.
    1. Helms J, Severac F, Merdji H, Schenck M, Clere-Jehl R, Baldacini M, et al. Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study. Ann Intensive Care. 2021;11(1):14. doi: 10.1186/s13613-021-00809-5.
    1. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–1098. doi: 10.1007/s00134-020-06062-x.
    1. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–124. doi: 10.1016/j.jacc.2020.05.001.
    1. Investigators I, Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620–1630. doi: 10.1001/jama.2021.4152.
    1. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000;52(2):237–268.
    1. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–851. doi: 10.1056/NEJMra1208623.
    1. Weinbaum S, Cancel LM, Fu BM, Tarbell JM. The glycocalyx and its role in vascular physiology and vascular related diseases. Cardiovasc Eng Technol. 2020;12:37–71. doi: 10.1007/s13239-020-00485-9.
    1. Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care. 2019;23(1):16. doi: 10.1186/s13054-018-2292-6.
    1. Song JW, Zullo JA, Liveris D, Dragovich M, Zhang XF, Goligorsky MS. Therapeutic restoration of endothelial glycocalyx in sepsis. J Pharmacol Exp Ther. 2017;361(1):115–121. doi: 10.1124/jpet.116.239509.
    1. Carsetti A, Damiani E, Casarotta E, Scorcella C, Domizi R, Montomoli J, et al. Sublingual microcirculation in patients with SARS-CoV-2 Undergoing Veno-Venous Extracorporeal Membrane Oxygenation. Microvasc Res. 2020;132:104064. doi: 10.1016/j.mvr.2020.104064.
    1. Damiani E, Carsetti A, Casarotta E, Scorcella C, Domizi R, Adrario E, et al. Microvascular alterations in patients with SARS-COV-2 severe pneumonia. Ann Intensive Care. 2020;10(1):60. doi: 10.1186/s13613-020-00680-w.
    1. Rovas A, Osiaevi I, Buscher K, Sackarnd J, Tepasse PR, Fobker M, et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis. 2020;24:145–157. doi: 10.1007/s10456-020-09753-7.
    1. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681–686. doi: 10.1016/S2213-2600(20)30243-5.
    1. Drost CC, Rovas A, Kusche-Vihrog K, Van Slyke P, Kim H, Hoang VC, et al. Tie2 activation promotes protection and reconstitution of the endothelial glycocalyx in human sepsis. Thromb Haemost. 2019;119(11):1827–1838. doi: 10.1055/s-0039-1695768.
    1. Rovas A, Seidel LM, Vink H, Pohlkotter T, Pavenstadt H, Ertmer C, et al. Association of sublingual microcirculation parameters and endothelial glycocalyx dimensions in resuscitated sepsis. Crit Care. 2019;23(1):260. doi: 10.1186/s13054-019-2542-2.
    1. Lee DH, Dane MJ, van den Berg BM, Boels MG, van Teeffelen JW, de Mutsert R, et al. Deeper penetration of erythrocytes into the endothelial glycocalyx is associated with impaired microvascular perfusion. PLoS ONE. 2014;9(5):e96477. doi: 10.1371/journal.pone.0096477.
    1. Stahl K, Gronski PA, Kiyan Y, Seeliger B, Bertram A, Pape T, et al. Injury to the endothelial glycocalyx in critically Ill patients with COVID-19. Am J Respir Crit Care Med. 2020;202(8):1178–1181. doi: 10.1164/rccm.202007-2676LE.
    1. Fraser DD, Patterson EK, Slessarev M, Gill SE, Martin C, Daley M, et al. Endothelial Injury and glycocalyx degradation in critically Ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation. Crit Care Explor. 2020;2(9):e0194. doi: 10.1097/CCE.0000000000000194.
    1. Potje SR, Costa TJ, Fraga-Silva TFC, Martins RB, Benatti MN, Almado CEL, et al. Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients. Life Sci. 2021;276:119376. doi: 10.1016/j.lfs.2021.119376.
    1. Buijsers B, Yanginlar C, de Nooijer A, Grondman I, Maciej-Hulme ML, Jonkman I, et al. Increased Plasma Heparanase Activity in COVID-19 Patients. Front Immunol. 2020;11:575047. doi: 10.3389/fimmu.2020.575047.
    1. Tandon R, Sharp JS, Zhang F, Pomin VH, Ashpole NM, Mitra D, et al. Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives. J Virol. 2021 doi: 10.1128/JVI.01987-20.
    1. Gowd V, Gurukar A, Chilkunda ND. Glycosaminoglycan remodeling during diabetes and the role of dietary factors in their modulation. World J Diabetes. 2016;7(4):67–73. doi: 10.4239/wjd.v7.i4.67.
    1. Kim SY, Jin W, Sood A, Montgomery DW, Grant OC, Fuster MM, et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res. 2020;181:104873. doi: 10.1016/j.antiviral.2020.104873.
    1. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000;6(4):460–463. doi: 10.1038/74725.
    1. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87(7):1161–1169. doi: 10.1016/S0092-8674(00)81812-7.
    1. Hakanpaa L, Sipila T, Leppanen VM, Gautam P, Nurmi H, Jacquemet G, et al. Endothelial destabilization by angiopoietin-2 via integrin beta1 activation. Nat Commun. 2015;6:5962. doi: 10.1038/ncomms6962.
    1. Hakanpaa L, Kiss EA, Jacquemet G, Miinalainen I, Lerche M, Guzman C, et al. Targeting beta1-integrin inhibits vascular leakage in endotoxemia. Proc Natl Acad Sci USA. 2018;115(28):E6467–E6476. doi: 10.1073/pnas.1722317115.
    1. Kumpers P, Lukasz A, David S, Horn R, Hafer C, Faulhaber-Walter R, et al. Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care. 2008;12(6):R147. doi: 10.1186/cc7130.
    1. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karumanchi SA, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS medicine. 2006;3(3):e46. doi: 10.1371/journal.pmed.0030046.
    1. Sack KD, Kellum JA, Parikh SM. The angiopoietin-Tie2 pathway in critical illness. Crit Care Clin. 2020;36(2):201–216. doi: 10.1016/j.ccc.2019.12.003.
    1. Smadja DM, Guerin CL, Chocron R, Yatim N, Boussier J, Gendron N, et al. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients. Angiogenesis. 2020;23(4):611–620. doi: 10.1007/s10456-020-09730-0.
    1. Vassiliou AG, Keskinidou C, Jahaj E, Gallos P, Dimopoulou I, Kotanidou A, et al. ICU admission levels of endothelial biomarkers as predictors of mortality in critically Ill COVID-19 patients. Cells. 2021;10(1):186. doi: 10.3390/cells10010186.
    1. Kumpers P, Lukasz A. The curse of angiopoietin-2 in ARDS: on stranger TI(E)des. Crit Care. 2018;22(1):44. doi: 10.1186/s13054-018-1978-0.
    1. Bermejo-Martin JF, Gonzalez-Rivera M, Almansa R, Micheloud D, Tedim AP, Dominguez-Gil M, et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit Care. 2020;24(1):691. doi: 10.1186/s13054-020-03398-0.
    1. Pine AB, Meizlish ML, Goshua G, Chang CH, Zhang H, Bishai J, et al. Circulating markers of angiogenesis and endotheliopathy in COVID-19. Pulm Circ. 2020;10(4):2045894020966547. doi: 10.1177/2045894020966547.
    1. Smadja DM, Philippe A, Bory O, Gendron N, Beauvais A, Gruest M, et al. Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality. J Thromb Haemost. 2021 doi: 10.1111/jth.15339.
    1. Byzova TV. "Fishing" out the real VEGFs. Blood. 2016;128(19):2283–2284. doi: 10.1182/blood-2016-09-737023.
    1. Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H. VEGF-D: a novel biomarker for detection of COVID-19 progression. Crit Care. 2020;24(1):373. doi: 10.1186/s13054-020-03079-y.
    1. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–128. doi: 10.1056/NEJMoa2015432.
    1. Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20(2):185–204. doi: 10.1007/s10456-017-9552-y.
    1. Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res. 2011;108(9):1063–1070. doi: 10.1161/CIRCRESAHA.110.239665.
    1. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658. doi: 10.1172/JCI17189.
    1. Dupont V, Kanagaratnam L, Goury A, Poitevin G, Bard M, Julien G, et al. Excess soluble fms-like tyrosine kinase 1 correlates with endothelial dysfunction and organ failure in critically ill COVID-19 patients. Clin Infect Dis. 2020;72:1834–1837. doi: 10.1093/cid/ciaa1007.
    1. Giardini V, Carrer A, Casati M, Contro E, Vergani P, Gambacorti-Passerini C. Increased sFLT-1/PlGF ratio in COVID-19: a novel link to angiotensin II-mediated endothelial dysfunction. Am J Hematol. 2020;95(8):E188–E191. doi: 10.1002/ajh.25882.
    1. Negro A, Fama A, Penna D, Belloni L, Zerbini A, Giuri PG. SFLT-1 levels in COVID-19 patients: Association with outcome and thrombosis. Am J Hematol. 2020 doi: 10.1002/ajh.26037.
    1. Mendoza M, Garcia-Ruiz I, Maiz N, Rodo C, Garcia-Manau P, Serrano B, et al. Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study. BJOG. 2020;127(11):1374–1380. doi: 10.1111/1471-0528.16339.
    1. Li L, Huang M, Shen J, Wang Y, Wang R, Yuan C, et al. Serum levels of soluble platelet endothelial cell adhesion molecule 1 in COVID-19 patients are associated with disease severity. J Infect Dis. 2021;223(1):178–179. doi: 10.1093/infdis/jiaa642.
    1. Barrett TJ, Lee AH, Xia Y, Lin LH, Black M, Cotzia P, et al. Platelet and vascular biomarkers associate with thrombosis and death in coronavirus disease. Circ Res. 2020;127(7):945–947. doi: 10.1161/CIRCRESAHA.120.317803.
    1. Borgel D, Chocron R, Grimaud M, Philippe A, Chareyre J, Brakta C, et al. Endothelial dysfunction as a component of SARS-CoV-2-related multisystem inflammatory syndrome in children with shock. Crit Care. 2021 doi: 10.1097/CCM.0000000000005093.
    1. McCormack JJ, Lopes da Silva M, Ferraro F, Patella F, Cutler DF (2017) Weibel-palade bodies at a glance. J Cell Sci 130(21):3611-3617
    1. Philippe A, Chocron R, Gendron N, Bory O, Beauvais A, Peron N, et al. Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis. 2021 doi: 10.1007/s10456-020-09762-6.
    1. von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundstrom A, Rudberg AS, Magnusson M, et al. Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. Res Pract Thromb Haemost. 2021;5(1):132–141. doi: 10.1002/rth2.12462.
    1. Dupont A, Rauch A, Staessens S, Moussa M, Rosa M, Corseaux D, et al. Vascular endothelial damage in the pathogenesis of organ injury in severe COVID-19. Arterioscler Thromb Vasc Biol. 2021;41(5):1760–1773. doi: 10.1161/ATVBAHA.120.315595.
    1. Bazzan M, Montaruli B, Sciascia S, Cosseddu D, Norbiato C, Roccatello D. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. Intern Emerg Med. 2020;15(5):861–863. doi: 10.1007/s11739-020-02394-0.
    1. Blasi A, von Meijenfeldt FA, Adelmeijer J, Calvo A, Ibanez C, Perdomo J, et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. J Thromb Haemost. 2020;18(10):2646–2653. doi: 10.1111/jth.15043.
    1. Rodriguez Rodriguez M, Castro Quismondo N, Zafra Torres D, Gil Alos D, Ayala R, Martinez-Lopez J. Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients. Int J Lab Hematol. 2021 doi: 10.1111/ijlh.13476.
    1. Escher R, Breakey N, Lammle B. ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients. Thromb Res. 2020;192:174–175. doi: 10.1016/j.thromres.2020.05.032.
    1. Turecek PL, Peck RC, Rangarajan S, Reilly-Stitt C, Laffan MA, Kazmi R, et al. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thromb Res. 2021;201:100–112. doi: 10.1016/j.thromres.2021.02.012.
    1. Doevelaar AAN, Bachmann M, Holzer B, Seibert FS, Rohn BJ, Bauer F, et al. von Willebrand factor multimer formation contributes to immunothrombosis in coronavirus disease 2019. Crit Care Med. 2021;49(5):e512–e520. doi: 10.1097/CCM.0000000000004918.
    1. Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021;19(2):513–521. doi: 10.1111/jth.15191.
    1. Kwaan HC. Microvascular thrombosis: a serious and deadly pathologic process in multiple diseases. Semin Thromb Hemost. 2011;37(8):961–978. doi: 10.1055/s-0031-1297375.
    1. Chavkin NW, Hirschi KK. Single cell analysis in vascular biology. Front Cardiovasc Med. 2020 doi: 10.3389/fcvm.2020.00042.
    1. Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med. 2012;2(1):e006429. doi: 10.1101/cshperspect.a006429.
    1. Liu J, Yuan L, Molema G, Regan E, Janes L, Beeler D, et al. Vascular bed-specific regulation of the von Willebrand factor promoter in the heart and skeletal muscle. Blood. 2011;117(1):342–351. doi: 10.1182/blood-2010-06-287987.
    1. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2006;54(4):385–395. doi: 10.1369/jhc.4A6514.2005.
    1. Yamamoto K, de Waard V, Fearns C, Loskutoff DJ. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo. Blood. 1998;92(8):2791–2801. doi: 10.1182/blood.V92.8.2791.
    1. Cattaneo M, Bertinato EM, Birocchi S, Brizio C, Malavolta D, Manzoni M, et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020;120:1230–1232. doi: 10.1055/s-0040-1712097.
    1. Falasca L, Nardacci R, Colombo D, Lalle E, Di Caro A, Nicastri E, et al. Postmortem findings in italian patients with COVID-19: a descriptive full autopsy study of cases with and without comorbidities. J Infect Dis. 2020;222(11):1807–1815. doi: 10.1093/infdis/jiaa578.
    1. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(10):1135–1140. doi: 10.1016/S1473-3099(20)30434-5.
    1. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120–128. doi: 10.1056/NEJMoa2015432.
    1. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020;173(5):350–361. doi: 10.7326/M20-2566.
    1. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Res 191:145-147
    1. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995–2002. doi: 10.1111/jth.14888.
    1. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020;201(10):1299–1300. doi: 10.1164/rccm.202003-0817LE.
    1. Patel BV, Arachchillage D, A R, Bianchi P, Doyle JF, Garfield B, et al (2020) Pulmonary angiopathy in severe Covid-19: surrogate physiologic, imaging and hematologic observations. Am J Respirat Crit Care Med 202(5):690–699
    1. Si-Mohamed S, Chebib N, Sigovan M, Zumbihl L, Turquier S, Boccalini S, et al. In vivo demonstration of pulmonary microvascular involvement in COVID-19 using dual-energy computed tomography. Eur Respir J. 2020;56(4):10. doi: 10.1183/13993003.02608-2020.
    1. Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, Ferraz da Silva LF, Pierre de Oliveira E, Nascimento Saldiva PH, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thrombosis Haemostasis. 2020;18(6):1517–1519. doi: 10.1111/jth.14844.
    1. The Severe Covid-19 GWAS Group Genomewide association study of severe covid-19 with respiratory failure. N Engl J Med. 2020;383(16):1522–1534. doi: 10.1056/NEJMoa2020283.
    1. O'Sullivan JM, Ward S, Fogarty H, O'Donnell JS. More on 'Association between ABO blood groups and risk of SARS-CoV-2 pneumonia'. Br J Haematol. 2020;190(1):27–28. doi: 10.1111/bjh.16845.
    1. Wu SC, Arthur CM, Wang J, Verkerke H, Josephson CD, Kalman D, et al. The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. Blood Adv. 2021;5(5):1305–1309. doi: 10.1182/bloodadvances.2020003259.
    1. Leppkes M, Knopf J, Naschberger E, Lindemann A, Singh J, Herrmann I, et al. Vascular occlusion by neutrophil extracellular traps in COVID-19. EBioMedicine. 2020;58:102925. doi: 10.1016/j.ebiom.2020.102925.
    1. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–1033. doi: 10.3390/v4061011.
    1. Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest. 2009;136(6):1631–1643. doi: 10.1378/chest.08-2408.
    1. Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc Disord. 2015;15(1):130. doi: 10.1186/s12872-015-0124-z.
    1. Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020;18(7):1548–1555. doi: 10.1111/jth.14872.
    1. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. 2020;395(10234):1417–1418. doi: 10.1016/S0140-6736(20)30937-5.
    1. Goldsmith CS, Miller SE, Martines RB, Bullock HA, Zaki SR. Electron microscopy of SARS-CoV-2: a challenging task. The Lancet. 2020;395(10238):99. doi: 10.1016/S0140-6736(20)31188-0.
    1. Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–13.e7. doi: 10.1016/j.cell.2020.04.004.
    1. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–1100. doi: 10.1093/cvr/cvaa078.
    1. McCracken IR, Saginc G, He L, Huseynov A, Daniels A, Fletcher S, et al. Lack of evidence of ACE2 expression and replicative infection by SARSCoV-2 in human endothelial cells. Circulation. 2021;143(8):865–868. doi: 10.1161/CIRCULATIONAHA.120.052824.
    1. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi: 10.1002/path.1570.
    1. Karuppan MKM, Devadoss D, Nair M, Chand HS, Lakshmana MK. SARS-CoV-2 infection in the central and peripheral nervous system-associated morbidities and their potential mechanism. Mol Neurobiol. 2021;13:1–16.
    1. Park EJ, Myint PK, Appiah MG, Darkwah S, Caidengbate S, Ito A, Matsuo E, Kawamoto E, Gaowa A, Shimaoka M. The spike glycoprotein of SARS-CoV-2 binds to β1 integrins expressed on the surface of lung epithelial cells. Viruses. 2021;13(4):645. doi: 10.3390/v13040645.
    1. Makowski L, Olson-Sidford W, Weisel JW. Biological and clinical consequences of integrin binding via a rogue RGD motif in the SARS CoV-2 spike protein. Viruses. 2021;13(2):146. doi: 10.3390/v13020146.
    1. Nolte MA, Nolte-'t ENM, Margadant HC. Integrins control vesicular trafficking; new tricks for old dogs. Trends Biochem Sci. 2021;46(2):124–137. doi: 10.1016/j.tibs.2020.09.001.
    1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 2020;130(5):2620–2629. doi: 10.1172/JCI137244.
    1. Reglero-Real N, Colom B, Bodkin JV, Nourshargh S. Endothelial cell junctional adhesion molecules. Arterioscler Thromb Vasc Biol. 2016;36(10):2048–2057. doi: 10.1161/ATVBAHA.116.307610.
    1. van der Bijl I, Nawaz K, Kazlauskaite U, van Stalborch A-M, Tol S, Jimenez A, van den Bout OI, Reinhard NR, Sonnenberg A, Margadant C. Reciprocal integrin/integrin antagonism through kindlin-2 and Rho GTPases regulates cell cohesion and collective migration. Matrix Biol. 2020;93:60–78. doi: 10.1016/j.matbio.2020.05.005.
    1. Yamamoto H, Ehling M, Kato K, Kanai K, van Lessen M, Frye M, Zeuschner D, Nakayama M, Vestweber D, Adams RH. Integrin β1 controls VE-cadherin localization and blood vessel stability. Nat Commun. 2015 doi: 10.1038/ncomms7429.
    1. Rauch A, Dupont A, Goutay J, Caplan M, Staessens S, Moussa M, et al. Endotheliopathy is induced by plasma from critically Ill patients and associated with organ failure in severe COVID-19. Circulation. 2020;142(19):1881–1884. doi: 10.1161/CIRCULATIONAHA.120.050907.
    1. Polidoro RB, Hagan RS, de Santis SR, Schmidt NW. Overview: systemic inflammatory response derived from lung injury caused by SARS-COV-2 infection explains severe outcomes in COVID-19. Front Immunol. 2020;11:1626. doi: 10.3389/fimmu.2020.01626.
    1. Teuwen L-A, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20(7):389–391. doi: 10.1038/s41577-020-0343-0.
    1. Arachchillage D, Shi C, Saliu D, Kozman P, Emma Mi4, Buti N, et al (2020) Efficacy and safety and of D-dimer, weight, and renal function adjusted thromboprophylaxis in patients with coronavirus disease 2019 (COVID-19). Semin Thromb Hemost 47(4):436-441
    1. Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg BS, Levin MA, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am College Cardiol. 2020 doi: 10.1016/j.jacc.2020.05.001.
    1. Smadja DM, Gaussem P, Mauge L, Israel-Biet D, Dignat-George F, Peyrard S, et al. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation. 2009;119(3):374–381. doi: 10.1161/CIRCULATIONAHA.108.808246.
    1. Chocron R, Galand V, Cellier J, Gendron N, Pommier T, Bory O, et al. Anticoagulation prior to hospitalization is a potential protective factor for COVID-19: insight from a French multicenter cohort study. J Am Heart Assoc. 2021;10:1018288.
    1. Medcalf RL, Keragala CB, Myles PS. Fibrinolysis and COVID-19: a plasmin paradox. J Thromb Haemost. 2020;18(9):2118–2122. doi: 10.1111/jth.14960.
    1. Arachchillage DJ, Stacey A, Akor F, Scotz M, Laffan M. Thrombolysis restores perfusion in COVID-19 hypoxia. Br J Haematol. 2020;190(5):e270–e274.
    1. Wu Y, Wang T, Guo C, Zhang D, Ge X, Huang Z, et al. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19. QJM. 2020;113(8):539–545. doi: 10.1093/qjmed/hcaa121.
    1. Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Science Reports. 2021;11(1):1580. doi: 10.1038/s41598-020-80010-z.
    1. Denorme F, Langhauser F, Desender L, Vandenbulcke A, Rottensteiner H, Plaimauer B, et al. ADAMTS13-mediated thrombolysis of t-PA–resistant occlusions in ischemic stroke in mice. Blood. 2016;127(19):2337–2345. doi: 10.1182/blood-2015-08-662650.
    1. Turecek P, Peck R, Rangarajan S, Reilly-Stitt C, Laffan M, Kazmi R, et al. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thrombosis Research. 2021;201:100–112. doi: 10.1016/j.thromres.2021.02.012.
    1. Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, et al. Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. Am J Hematol. 2021;96(4):471–479. doi: 10.1002/ajh.26102.
    1. Dutt T, Shaw RJ, Stubbs M, Yong J, Bailiff B, Cranfield T, et al. Real-world experience with caplacizumab in the management of acute TTP. Blood. 2021;137(13):1731–1740. doi: 10.1182/blood.2020007599.
    1. Zheng L, Mao Y, Abdelgawwad MS, Kocher NK, Li M, Dai X, et al. Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura. Blood Adv. 2016;1:75–83. doi: 10.1182/bloodadvances.2016000711.
    1. Rahimi A, Samimagham HR, Azad MH, Hooshyar D, Arabi M, KazemiJahromi M. The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22(1):271. doi: 10.1186/s13063-021-05242-4.
    1. Amado-Azevedo J, van Stalborch AD, Valent ET, Nawaz K, van Bezu J, Eringa EC, et al. Depletion of Arg/Abl2 improves endothelial cell adhesion and prevents vascular leak during inflammation. Angiogenesis. 2021 doi: 10.1007/s10456-021-09781-x.
    1. Aman J, Duijvelaar E, Botros L, Kianzad A, J.R.Schippers, Smeele PJ, et al (2021) A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with 5 severe COVID-19. Lancet Resp Med In Press
    1. Noh JY, Yoon JG, Seong H, Choi WS, Sohn JW, Cheong HJ, et al. Asymptomatic infection and atypical manifestations of COVID-19: Comparison of viral shedding duration. J Infect. 2020;81(5):816–846. doi: 10.1016/j.jinf.2020.05.035.
    1. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–675. doi: 10.1038/s41591-020-0869-5.
    1. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–1179. doi: 10.1056/NEJMc2001737.
    1. Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study. AJR Am J Roentgenol. 2020;214(5):1072–1077. doi: 10.2214/AJR.20.22976.
    1. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol. 2020;215(1):87–93. doi: 10.2214/AJR.20.23034.
    1. Ackermann M, Mentzer SJ, Jonigk D. Pulmonary vascular pathology in Covid-19. Reply N Engl J Med. 2020;383(9):888–889.
    1. Ackermann M, Mentzer SJ, Jonigk D. Visualization of SARS-CoV-2 in the lung. Reply N Engl J Med. 2020;383(27):2689–2690. doi: 10.1056/NEJMc2030450.
    1. Tobin MJ, Laghi F, Jubran A. Why COVID-19 silent hypoxemia is baffling to physicians. Am J Respir Crit Care Med. 2020;202(3):356–360. doi: 10.1164/rccm.202006-2157CP.
    1. Couzin-Frankel J. The mystery of the pandemic's 'happy hypoxia'. Science. 2020;368(6490):455–456. doi: 10.1126/science.368.6490.455.
    1. Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. The pathophysiology of 'happy' hypoxemia in COVID-19. Respir Res. 2020;21(1):198. doi: 10.1186/s12931-020-01462-5.
    1. Sylvester JT, Shimoda LA, Aaronson PI, Ward JP. Hypoxic pulmonary vasoconstriction. Physiol Rev. 2012;92(1):367–520. doi: 10.1152/physrev.00041.2010.
    1. Wang L, Yin J, Nickles HT, Ranke H, Tabuchi A, Hoffmann J, et al. Hypoxic pulmonary vasoconstriction requires connexin 40-mediated endothelial signal conduction. J Clin Invest. 2012;122(11):4218–4230. doi: 10.1172/JCI59176.
    1. Herrmann J, Mori V, Bates JHT, Suki B. Modeling lung perfusion abnormalities to explain early COVID-19 hypoxemia. Nat Commun. 2020;11(1):4883. doi: 10.1038/s41467-020-18672-6.
    1. Slessarev M, Cheng J, Ondrejicka M, Arntfield R. Critical care western research G. Patient self-proning with high-flow nasal cannula improves oxygenation in COVID-19 pneumonia. Can J Anaesth. 2020;67(9):1288–1290. doi: 10.1007/s12630-020-01661-0.
    1. Caputo ND, Strayer RJ, Levitan R. Early self-proning in awake, non-intubated patients in the emergency department: a single ED's experience during the COVID-19 pandemic. Acad Emerg Med. 2020;27(5):375–378. doi: 10.1111/acem.13994.
    1. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388–393. doi: 10.1016/j.jinf.2020.02.016.
    1. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:33. doi: 10.1038/s41392-020-0148-4.
    1. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535. doi: 10.1038/s41423-020-0402-2.
    1. Caduff JH, Fischer LC, Burri PH. Scanning electron microscope study of the developing microvasculature in the postnatal rat lung. Anat Rec. 1986;216(2):154–164. doi: 10.1002/ar.1092160207.
    1. Filipovic N, Tsuda A, Lee GS, Miele LF, Lin M, Konerding MA, et al. Computational flow dynamics in a geometric model of intussusceptive angiogenesis. Microvasc Res. 2009;78(3):286–293. doi: 10.1016/j.mvr.2009.08.004.
    1. Lee GS, Filipovic N, Lin M, Gibney BC, Simpson DC, Konerding MA, et al. Intravascular pillars and pruning in the extraembryonic vessels of chick embryos. Dev Dyn. 2011;240(6):1335–1343. doi: 10.1002/dvdy.22618.
    1. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–2533.
    1. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012;38(10):1573–1582. doi: 10.1007/s00134-012-2682-1.
    1. Greene R, Lind S, Jantsch H, Wilson R, Lynch K, Jones R, et al. Pulmonary vascular obstruction in severe ARDS: angiographic alterations after i.v. fibrinolytic therapy. AJR Am J Roentgenol. 1987;148(3):501–508. doi: 10.2214/ajr.148.3.501.
    1. Tomashefski JF, Jr, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol. 1983;112(1):112–126.
    1. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med. 2002;346(17):1281–1286. doi: 10.1056/NEJMoa012835.
    1. Chiumello D, Busana M, Coppola S, Romitti F, Formenti P, Bonifazi M, et al. Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study. Intensive Care Med. 2020;46(12):2187–2196. doi: 10.1007/s00134-020-06281-2.
    1. Goligher EC, Ranieri VM, Slutsky AS. Is severe COVID-19 pneumonia a typical or atypical form of ARDS? And does it matter? Intensive Care Med. 2021;47(1):83–85. doi: 10.1007/s00134-020-06320-y.
    1. Beloncle FM, Pavlovsky B, Desprez C, Fage N, Olivier PY, Asfar P, et al. Recruitability and effect of PEEP in SARS-Cov-2-associated acute respiratory distress syndrome. Ann Intensive Care. 2020;10(1):55. doi: 10.1186/s13613-020-00675-7.
    1. Sinha P, Fauvel NJ, Singh P, Soni N. Analysis of ventilatory ratio as a novel method to monitor ventilatory adequacy at the bedside. Crit Care. 2013;17(1):R34. doi: 10.1186/cc12541.
    1. Caviedes I, Soto R, Torres A. Pulmonary angiopathy in severe COVID-19: physiological conclusions derived from ventilatory ratio? Am J Respir Crit Care Med. 2021;203(2):258–259. doi: 10.1164/rccm.202009-3446LE.
    1. Carsetti A, Damiani E, Casarotta E, Scorcella C, Domizi R, Montomoli J, et al (2020) Sublingual microcirculation in patients with SARS-CoV-2 undergoing veno-venous extracorporeal membrane oxygenation. Microvasc Res 132:104064
    1. Kanoore Edul VS, Caminos Eguillor JF, Ferrara G, Estenssoro E, Siles DSP, Cesio CE, et al. Microcirculation alterations in severe COVID-19 pneumonia. J Crit Care. 2021;61:73–75. doi: 10.1016/j.jcrc.2020.10.002.
    1. do Espirito Santo DA, Lemos ACB, Miranda CH (2020) In vivo demonstration of microvascular thrombosis in severe COVID-19. J Thromb Thrombolysis 50(4):790–794
    1. Ospina-Tascon GA, Bautista DF, Madrinan HJ, Valencia JD, Bermudez WF, Quinones E, et al. Microcirculatory dysfunction and dead-space ventilation in early ARDS: a hypothesis-generating observational study. Ann Intensive Care. 2020;10(1):35. doi: 10.1186/s13613-020-00651-1.
    1. Diehl JL, Peron N, Philippe A, Smadja DM. Response to Damiani and colleagues. Ann Intensive Care. 2020;10(1):140. doi: 10.1186/s13613-020-00757-6.
    1. Patel BV, Arachchillage DJ, Ridge CA, Bianchi P, Doyle JF, Garfield B, et al. Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations. Am J Respir Crit Care Med. 2020;202(5):690–699. doi: 10.1164/rccm.202004-1412OC.
    1. Lang M, Som A, Mendoza DP, Flores EJ, Reid N, Carey D, et al. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT. Lancet Infect Dis. 2020;20(12):1365–1366. doi: 10.1016/S1473-3099(20)30367-4.
    1. Beenen LFM, Bos LD, Scheerder MJ, Lobe NHJ, Muller MCA, Schultz MJ, et al. Extensive pulmonary perfusion defects compatible with microthrombosis and thromboembolic disease in severe Covid-19 pneumonia. Thromb Res. 2020;196:135–137. doi: 10.1016/j.thromres.2020.08.026.
    1. Mauri T, Spinelli E, Scotti E, Colussi G, Basile MC, Crotti S, et al. Potential for lung recruitment and ventilation-perfusion mismatch in patients with the acute respiratory distress syndrome from coronavirus disease 2019. Crit Care Med. 2020;48(8):1129–1134. doi: 10.1097/CCM.0000000000004386.
    1. Sella N, Zarantonello F, Andreatta G, Gagliardi V, Boscolo A, Navalesi P. Positive end-expiratory pressure titration in COVID-19 acute respiratory failure: electrical impedance tomography vs. PEEP/FiO2 tables. Crit Care. 2020;24(1):540. doi: 10.1186/s13054-020-03242-5.
    1. Safaee Fakhr B, Araujo Morais CC, De Santis Santiago RR, Di Fenza R, Gibson LE, Restrepo PA, et al. Bedside monitoring of lung perfusion by electrical impedance tomography in the time of COVID-19. Br J Anaesth. 2020;125(5):e434–e436. doi: 10.1016/j.bja.2020.08.001.
    1. Lerum TV, Aalokken TM, Bronstad E, Aarli B, Ikdahl E, Lund KMA, et al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J. 2021;57(4):2003448. doi: 10.1183/13993003.03448-2020.
    1. Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. 2020;55(6):2001217. doi: 10.1183/13993003.01217-2020.
    1. Dhawan RT, Gopalan D, Howard L, Vicente A, Park M, Manalan K, et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir Med. 2021;9(1):107–116. doi: 10.1016/S2213-2600(20)30407-0.
    1. Chapman DG, Badal T, King GG, Thamrin C. Caution in interpretation of abnormal carbon monoxide diffusion capacity in COVID-19 patients. Eur Respir J. 2021;57(1):2003263. doi: 10.1183/13993003.03263-2020.
    1. Pfaender S, Mar KB, Michailidis E, Kratzel A, Boys IN, V'Kovski P, et al. LY6E impairs coronavirus fusion and confers immune control of viral disease. Nat Microbiol. 2020;5(11):1330–1339. doi: 10.1038/s41564-020-0769-y.
    1. Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, et al (2020) Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell 182(6):1401–18e18
    1. Schulte-Schrepping J, Reusch N, Paclik D, Bassler K, Schlickeiser S, Zhang B, et al (2020) Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 182(6):1419–40e23
    1. Busch K, Klapproth K, Barile M, Flossdorf M, Holland-Letz T, Schlenner SM, et al. Fundamental properties of unperturbed haematopoiesis from stem cells in vivo. Nature. 2015;518(7540):542–546. doi: 10.1038/nature14242.
    1. Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol. 2010;10(3):201–209. doi: 10.1038/nri2726.
    1. Sun J, Ramos A, Chapman B, Johnnidis JB, Le L, Ho YJ, et al. Clonal dynamics of native haematopoiesis. Nature. 2014;514(7522):322–327. doi: 10.1038/nature13824.
    1. Cabezas-Wallscheid N, Klimmeck D, Hansson J, Lipka DB, Reyes A, Wang Q, et al. Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. Cell Stem Cell. 2014;15(4):507–522. doi: 10.1016/j.stem.2014.07.005.
    1. Notta F, Zandi S, Takayama N, Dobson S, Gan OI, Wilson G, et al. Distinct routes of lineage development reshape the human blood hierarchy across ontogeny. Science. 2016;351(6269):aab2116. doi: 10.1126/science.aab2116.
    1. Bassler K, Schulte-Schrepping J, Warnat-Herresthal S, Aschenbrenner AC, Schultze JL. The myeloid cell compartment-cell by cell. Annu Rev Immunol. 2019;37:269–293. doi: 10.1146/annurev-immunol-042718-041728.
    1. Pietras EM, Reynaud D, Kang YA, Carlin D, Calero-Nieto FJ, Leavitt AD, et al. Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions. Cell Stem Cell. 2015;17(1):35–46. doi: 10.1016/j.stem.2015.05.003.
    1. Herault A, Binnewies M, Leong S, Calero-Nieto FJ, Zhang SY, Kang YA, et al. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature. 2017;544(7648):53–58. doi: 10.1038/nature21693.
    1. Boettcher S, Manz MG. Regulation of inflammation- and infection-Driven Hematopoiesis. Trends Immunol. 2017;38(5):345–357. doi: 10.1016/j.it.2017.01.004.
    1. Baldridge MT, King KY, Boles NC, Weksberg DC, Goodell MA. Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature. 2010;465(7299):793–797. doi: 10.1038/nature09135.
    1. Manz MG, Boettcher S. Emergency granulopoiesis. Nat Rev Immunol. 2014;14(5):302–314. doi: 10.1038/nri3660.
    1. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904–908. doi: 10.1038/nature07815.
    1. Paschall AV, Zhang R, Qi CF, Bardhan K, Peng L, Lu G, et al. IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation. J Immunol. 2015;194(5):2369–2379. doi: 10.4049/jimmunol.1402412.
    1. Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity. 2006;24(6):801–812. doi: 10.1016/j.immuni.2006.04.008.
    1. Zhao JL, Ma C, O'Connell RM, Mehta A, DiLoreto R, Heath JR, et al. Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem Cell. 2014;14(4):445–459. doi: 10.1016/j.stem.2014.01.007.
    1. Takizawa H, Fritsch K, Kovtonyuk LV, Saito Y, Yakkala C, Jacobs K, et al (2017) Pathogen-induced TLR4-TRIF innate immune signaling in hematopoietic stem cells promotes proliferation but reduces competitive fitness. Cell Stem Cell 21(2):225–40 e5
    1. Boettcher S, Ziegler P, Schmid MA, Takizawa H, van Rooijen N, Kopf M, et al. Cutting edge: LPS-induced emergency myelopoiesis depends on TLR4-expressing nonhematopoietic cells. J Immunol. 2012;188(12):5824–5828. doi: 10.4049/jimmunol.1103253.
    1. Mitroulis I, Ruppova K, Wang B, Chen LS, Grzybek M, Grinenko T, et al (2018) Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell 172(1–2):147–61e12
    1. Pietras EM, Lakshminarasimhan R, Techner JM, Fong S, Flach J, Binnewies M, et al. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med. 2014;211(2):245–262. doi: 10.1084/jem.20131043.
    1. Kawano Y, Takaue Y, Hirao A, Abe T, Saito S, Matsunaga K, et al. Synergistic effect of recombinant interferon-gamma and interleukin-3 on the growth of immature human hematopoietic progenitors. Blood. 1991;77(10):2118–2121. doi: 10.1182/blood.V77.10.2118.2118.
    1. Schurch CM, Riether C, Ochsenbein AF. Cytotoxic CD8+ T cells stimulate hematopoietic progenitors by promoting cytokine release from bone marrow mesenchymal stromal cells. Cell Stem Cell. 2014;14(4):460–472. doi: 10.1016/j.stem.2014.01.002.
    1. Weber GF, Chousterman BG, He S, Fenn AM, Nairz M, Anzai A, et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science. 2015;347(6227):1260–1265. doi: 10.1126/science.aaa4268.
    1. Pietras EM, Mirantes-Barbeito C, Fong S, Loeffler D, Kovtonyuk LV, Zhang S, et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat Cell Biol. 2016;18(6):607–618. doi: 10.1038/ncb3346.
    1. Kandalla PK, Sarrazin S, Molawi K, Berruyer C, Redelberger D, Favel A, et al. M-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation. J Exp Med. 2016;213(11):2269–2279. doi: 10.1084/jem.20151975.
    1. Karmaus PWF, Herrada AA, Guy C, Neale G, Dhungana Y, Long L, et al. Critical roles of mTORC1 signaling and metabolic reprogramming for M-CSF-mediated myelopoiesis. J Exp Med. 2017;214(9):2629–2647. doi: 10.1084/jem.20161855.
    1. Mitroulis I, Chen LS, Singh RP, Kourtzelis I, Economopoulou M, Kajikawa T, et al. Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche. J Clin Invest. 2017;127(10):3624–3639. doi: 10.1172/JCI92571.
    1. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020;217(6):e20200678. doi: 10.1084/jem.20200678.
    1. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al (2020) Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 27(6):992–1000e3
    1. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718–724. doi: 10.1126/science.abc6027.
    1. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al (2020) Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181(5):1036–45e9
    1. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52(6):910–941. doi: 10.1016/j.immuni.2020.05.002.
    1. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584(7821):463–469. doi: 10.1038/s41586-020-2588-y.
    1. Liepelt A, Hohlstein P, Gussen H, Xue J, Aschenbrenner AC, Ulas T, et al. Differential gene expression in circulating CD14(+) monocytes indicates the prognosis of critically Ill patients with sepsis. J Clin Med. 2020;9(1):127. doi: 10.3390/jcm9010127.
    1. Reyes M, Filbin MR, Bhattacharyya RP, Billman K, Eisenhaure T, Hung DT, et al. An immune-cell signature of bacterial sepsis. Nat Med. 2020;26(3):333–340. doi: 10.1038/s41591-020-0752-4.
    1. Mann ER, Menon M, Knight SB, Konkel JE, Jagger C, Shaw TN, et al (2020) Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. Sci Immunol 5(51) :eabd6197
    1. Meghraoui-Kheddar A, Barthelemy S, Boissonnas A, Combadiere C. Revising CX3CR1 expression on murine classical and non-classical monocytes. Front Immunol. 2020;11:1117. doi: 10.3389/fimmu.2020.01117.
    1. Monneret G, Venet F. Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy. Cytometry B Clin Cytom. 2016;90(4):376–386. doi: 10.1002/cyto.b.21270.
    1. Mengos AE, Gastineau DA, Gustafson MP. The CD14(+)HLA-DR(lo/neg) monocyte: an immunosuppressive phenotype that restrains responses to cancer immunotherapy. Front Immunol. 2019;10:1147. doi: 10.3389/fimmu.2019.01147.
    1. Darcy CJ, Minigo G, Piera KA, Davis JS, McNeil YR, Chen Y, et al. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit Care. 2014;18(4):R163. doi: 10.1186/cc14003.
    1. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Muller M, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med. 2010;207(7):1453–1464. doi: 10.1084/jem.20091474.
    1. Bost P, Giladi A, Liu Y, Bendjelal Y, Xu G, David E, et al (2020) Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell 181(7):1475–88 e12
    1. Reyes M, Filbin MR, Bhattacharyya RP, Sonny A, Mehta A, Billman K, et al (2020) Induction of a regulatory myeloid program in bacterial sepsis and severe COVID-19. bioRxiv
    1. Psaila B, Mead AJ. Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation. Blood. 2019;133(13):1427–1435. doi: 10.1182/blood-2018-11-835371.
    1. Yamamoto R, Morita Y, Ooehara J, Hamanaka S, Onodera M, Rudolph KL, et al. Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell. 2013;154(5):1112–1126. doi: 10.1016/j.cell.2013.08.007.
    1. Haas S, Hansson J, Klimmeck D, Loeffler D, Velten L, Uckelmann H, et al. Inflammation-induced emergency megakaryopoiesis driven by hematopoietic stem cell-like megakaryocyte progenitors. Cell Stem Cell. 2015;17(4):422–434. doi: 10.1016/j.stem.2015.07.007.
    1. Lefrancais E, Ortiz-Munoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, et al. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544(7648):105–109. doi: 10.1038/nature21706.
    1. Roncati L, Ligabue G, Nasillo V, Lusenti B, Gennari W, Fabbiani L, et al. A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients. Platelets. 2020;31(8):1085–1089. doi: 10.1080/09537104.2020.1810224.
    1. Valdivia-Mazeyra MF, Salas C, Nieves-Alonso JM, Martin-Fragueiro L, Barcena C, Munoz-Hernandez P, et al. Increased number of pulmonary megakaryocytes in COVID-19 patients with diffuse alveolar damage: an autopsy study with clinical correlation and review of the literature. Virchows Arch. 2021;478(3):487–496. doi: 10.1007/s00428-020-02926-1.
    1. Bernardes JP, Mishra N, Tran F, Bahmer T, Best L, Blase JI, et al (2020) Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19. Immunity 53(6):1296–314e9
    1. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–121. doi: 10.1056/NEJMoa1701719.
    1. Duployez N, Demonchy J, Berthon C, Goutay J, Caplan M, Moreau AS, et al. Clinico-biological features and clonal hematopoiesis in patients with severe COVID-19. Cancers (Basel). 2020;12(7):1992. doi: 10.3390/cancers12071992.
    1. Bolton KL, Koh Y, Foote MB, Im H, Jee J, Sun CH, et al (2020) Clonal hematopoiesis is associated with risk of severe Covid-19. medRxiv
    1. Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525(7569):389–393. doi: 10.1038/nature15252.
    1. Cai Z, Kotzin JJ, Ramdas B, Chen S, Nelanuthala S, Palam LR, et al (2018) Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell 23(6):833–49e5
    1. Shen Q, Zhang Q, Shi Y, Shi Q, Jiang Y, Gu Y, et al. Tet2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation. Nature. 2018;554(7690):123–127. doi: 10.1038/nature25434.
    1. Nagareddy PR, Kraakman M, Masters SL, Stirzaker RA, Gorman DJ, Grant RW, et al. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab. 2014;19(5):821–835. doi: 10.1016/j.cmet.2014.03.029.
    1. Garcia Luis, de Guadiana R, Mulero MDR, Olivo MH, Rojas CR, Arenas VR, Morales MG, et al. Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: A case series. J Infect. 2021;82(2):e40-e2.
    1. Chen L, Long X, Xu Q, Tan J, Wang G, Cao Y, et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell Mol Immunol. 2020;17(9):992–994. doi: 10.1038/s41423-020-0492-x.
    1. Shi H, Zuo Y, Yalavarthi S, Gockman K, Zuo M, Madison JA, et al. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. J Leukoc Biol. 2021;109(1):67–72. doi: 10.1002/JLB.3COVCRA0720-359R.
    1. Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in Inflammation. Front Immunol. 2018;9:1298. doi: 10.3389/fimmu.2018.01298.
    1. Ulas T, Pirr S, Fehlhaber B, Bickes MS, Loof TG, Vogl T, et al. S100-alarmin-induced innate immune programming protects newborn infants from sepsis. Nat Immunol. 2017;18(6):622–632. doi: 10.1038/ni.3745.
    1. Oduro KA, Jr, Liu F, Tan Q, Kim CK, Lubman O, Fremont D, et al. Myeloid skewing in murine autoimmune arthritis occurs in hematopoietic stem and primitive progenitor cells. Blood. 2012;120(11):2203–2213. doi: 10.1182/blood-2011-11-391342.
    1. Sreejit G, Abdel-Latif A, Athmanathan B, Annabathula R, Dhyani A, Noothi SK, et al. Neutrophil-derived S100A8/A9 amplify granulopoiesis after myocardial infarction. Circulation. 2020;141(13):1080–1094. doi: 10.1161/CIRCULATIONAHA.119.043833.
    1. Kraakman MJ, Lee MK, Al-Sharea A, Dragoljevic D, Barrett TJ, Montenont E, et al. Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes. J Clin Invest. 2017;127(6):2133–2147. doi: 10.1172/JCI92450.
    1. Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med. 2016;22(3):288–297. doi: 10.1038/nm.4047.
    1. Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016;128(25):2960–2975. doi: 10.1182/blood-2016-07-730556.
    1. Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013;123(11):4595–4611. doi: 10.1172/JCI67580.
    1. Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, et al. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes. Leukemia. 2019;33(8):2034–2046. doi: 10.1038/s41375-019-0397-9.
    1. Leimkuhler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, et al (2021) Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell 28(4):637–52 e8.
    1. Ratajczak MZ, Ratajczak J, Suszynska M, Miller DM, Kucia M, Shin DM. A novel view of the adult stem cell compartment from the perspective of a quiescent population of very small embryonic-like stem cells. Circ Res. 2017;120(1):166–178. doi: 10.1161/CIRCRESAHA.116.309362.
    1. Mancuso P, Gidaro A, Gregato G, Raveane A, Cremonesi P, Quarna J, et al. Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases. J Thromb Haemost. 2020;18(10):2744–2750. doi: 10.1111/jth.15044.
    1. Guerin CL, Guyonnet L, Goudot G, Revets D, Konstantinou M, Chipont A, et al. Multidimensional proteomic approach of endothelial progenitors demonstrate expression of KDR restricted to CD19 cells. Stem Cell Rev Rep. 2020 doi: 10.1007/s12015-020-10062-1.
    1. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020;71(16):2255–2258. doi: 10.1093/cid/ciaa489.
    1. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848. doi: 10.1038/s41591-020-0897-1.
    1. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2027–2034. doi: 10.1093/cid/ciaa344.
    1. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–1204. doi: 10.1038/s41591-020-0965-6.
    1. McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight. 2020 doi: 10.1172/jci.insight.142386.
    1. Phipps WS, SoRelle JA, Li QZ, Mahimainathan L, Araj E, Markantonis J, et al. SARS-CoV-2 antibody responses do not predict COVID-19 disease severity. Am J Clin Pathol. 2020;154(4):459–465. doi: 10.1093/ajcp/aqaa123.
    1. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, et al. Magnitude and kinetics of anti-severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity. Clin Infect Dis. 2021;72(2):301–308. doi: 10.1093/cid/ciaa979.
    1. Hu WT, Howell JC, Ozturk T, Benameur K, Bassit LC, Ramonell R, et al. Antibody profiles according to mild or severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020. Emerg Infect Dis. 2020;26(12):2974–2978. doi: 10.3201/eid2612.203334.
    1. Young BE, Ong SWX, Ng LFP, Anderson DE, Chia WN, Chia PY, et al. Viral dynamics and immune correlates of COVID-19 disease severity. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa1280.
    1. Amrun SN, Lee CY, Lee B, Fong SW, Young BE, Chee RS, et al. Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine. 2020;58:102911. doi: 10.1016/j.ebiom.2020.102911.
    1. Ren L, Fan G, Wu W, Guo L, Wang Y, Li X, et al. Antibody responses and clinical outcomes in adults hospitalized with severe coronavirus disease 2019 (COVID-19): a post hoc analysis of LOTUS China trial. Clin Infect Dis. 2021;72(10):e545–e551. doi: 10.1093/cid/ciaa1247.
    1. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020;130(10):5235–5244. doi: 10.1172/JCI138759.
    1. Casadevall A, Joyner MJ, Pirofski LA. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy. J Clin Invest. 2020;130(10):5112–5114. doi: 10.1172/JCI139760.
    1. Luo YR, Chakraborty I, Yun C, Wu AHB, Lynch KL. Kinetics of SARS-CoV-2 antibody avidity maturation and association with disease severity. Clin Infect Dis. 2020;10:2. doi: 10.1093/cid/ciaa1389.
    1. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi: 10.1001/jama.2020.4783.
    1. Szwebel TA, Veyer D, Robillard N, Eshagh D, Canoui E, Bruneau T, et al. Usefulness of plasma SARS-CoV-2 RNA quantification by droplet-based digital PCR to monitor treatment against COVID-19 in a B-cell lymphoma patient. Stem Cell Rev Rep. 2021;17(1):296–299. doi: 10.1007/s12015-020-10107-5.
    1. Hueso T, Pouderoux C, Pere H, Beaumont AL, Raillon LA, Ader F, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–2295. doi: 10.1182/blood.2020008423.
    1. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) BMJ. 2020;371:m3939. doi: 10.1136/bmj.m3939.
    1. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vazquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619–629. doi: 10.1056/NEJMoa2031304.
    1. Huijbers EJM, van Beijnum JR, Le CT, Langman S, Nowak-Sliwinska P, Mayo KH, et al. An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature. Vaccine. 2018;36(21):3054–3060. doi: 10.1016/j.vaccine.2018.03.064.
    1. Huijbers EJM, Griffioen AW. The revival of cancer vaccines—the eminent need to activate humoral immunity. Hum Vaccin Immunother. 2017;13(5):1112–1114. doi: 10.1080/21645515.2016.1276140.
    1. Smadja DM, Yue QY, Chocron R, Sanchez O, Lillo-Le Louet A. Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. Eur Respir J. 2021 doi: 10.1183/13993003.00956-2021.
    1. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101. doi: 10.1056/NEJMoa2104840.
    1. Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124–2130. doi: 10.1056/NEJMoa2104882.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren